IL234710A - Antibodies that neutralize mpv, rsv, and pvm and their uses - Google Patents

Antibodies that neutralize mpv, rsv, and pvm and their uses

Info

Publication number
IL234710A
IL234710A IL234710A IL23471014A IL234710A IL 234710 A IL234710 A IL 234710A IL 234710 A IL234710 A IL 234710A IL 23471014 A IL23471014 A IL 23471014A IL 234710 A IL234710 A IL 234710A
Authority
IL
Israel
Prior art keywords
mpv
pvm
antibodies
neutralize rsv
rsv
Prior art date
Application number
IL234710A
Other languages
English (en)
Hebrew (he)
Inventor
Corti Davide
Original Assignee
Humabs Biomed Sa
Corti Davide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Corti Davide filed Critical Humabs Biomed Sa
Publication of IL234710A publication Critical patent/IL234710A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL234710A 2012-03-20 2014-09-17 Antibodies that neutralize mpv, rsv, and pvm and their uses IL234710A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613197P 2012-03-20 2012-03-20
US201261655310P 2012-06-04 2012-06-04
PCT/IB2013/000627 WO2013140247A1 (en) 2012-03-20 2013-03-14 Antibodies that neutralize rsv, mpv and pvm and uses thereof

Publications (1)

Publication Number Publication Date
IL234710A true IL234710A (en) 2016-12-29

Family

ID=48471031

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234710A IL234710A (en) 2012-03-20 2014-09-17 Antibodies that neutralize mpv, rsv, and pvm and their uses

Country Status (16)

Country Link
US (4) US9498531B2 (enExample)
EP (1) EP2828293B1 (enExample)
JP (4) JP6445423B2 (enExample)
KR (1) KR102149069B1 (enExample)
CN (2) CN104350069B (enExample)
AU (1) AU2013237087B2 (enExample)
BR (1) BR112014023063A2 (enExample)
CA (1) CA2865856C (enExample)
DK (1) DK2828293T3 (enExample)
EA (1) EA030319B1 (enExample)
ES (1) ES2657470T3 (enExample)
IL (1) IL234710A (enExample)
IN (1) IN2014DN07299A (enExample)
NZ (1) NZ630920A (enExample)
PL (1) PL2828293T3 (enExample)
WO (1) WO2013140247A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2828293T3 (pl) 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2020160171A1 (en) * 2019-01-29 2020-08-06 Sanford Burnham Prebys Medical Discovery Institute Topically formulated antibody compositions for reducing pathogen transmission and methods of using same
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
TW202246317A (zh) * 2021-02-09 2022-12-01 瑞士商休曼生物醫藥股份公司 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
AU2022227761A1 (en) * 2021-02-26 2023-09-28 Fred Hutchinson Cancer Center Protective antibodies against respiratory viral infections
CN115466326B (zh) * 2021-06-11 2024-06-04 中国科学院微生物研究所 一种呼吸道合胞病毒的人源单克隆抗体及其应用
WO2025015321A1 (en) * 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
EP1473037A1 (en) 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2350128B1 (en) 2008-10-22 2014-10-01 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
AU2010264686A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
TWI539963B (zh) * 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
PL2828293T3 (pl) * 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania

Also Published As

Publication number Publication date
ES2657470T3 (es) 2018-03-05
US20210115114A1 (en) 2021-04-22
JP2015514068A (ja) 2015-05-18
US20140037648A1 (en) 2014-02-06
EP2828293B1 (en) 2017-10-25
US20170121393A1 (en) 2017-05-04
EA201491724A1 (ru) 2015-01-30
EP2828293A1 (en) 2015-01-28
CA2865856C (en) 2023-03-14
CN104350069B (zh) 2017-12-01
WO2013140247A1 (en) 2013-09-26
JP7069251B2 (ja) 2022-05-17
BR112014023063A2 (pt) 2017-07-18
JP6722264B2 (ja) 2020-07-15
CN104350069A (zh) 2015-02-11
JP2022132244A (ja) 2022-09-07
IN2014DN07299A (enExample) 2015-04-24
CN107880121B (zh) 2022-02-18
US10072071B2 (en) 2018-09-11
NZ630920A (en) 2017-01-27
US9498531B2 (en) 2016-11-22
KR102149069B1 (ko) 2020-08-28
CN107880121A (zh) 2018-04-06
KR20140135259A (ko) 2014-11-25
EA030319B1 (ru) 2018-07-31
JP6445423B2 (ja) 2018-12-26
HK1206367A1 (en) 2016-01-08
US20190153073A1 (en) 2019-05-23
JP2020182464A (ja) 2020-11-12
AU2013237087A1 (en) 2014-09-18
AU2013237087B2 (en) 2017-07-20
PL2828293T3 (pl) 2018-03-30
US11421020B2 (en) 2022-08-23
CA2865856A1 (en) 2013-09-26
JP2019076091A (ja) 2019-05-23
DK2828293T3 (en) 2018-01-08

Similar Documents

Publication Publication Date Title
IL238192B (en) Antibodies that recognize alpha-synuclei, preparations containing them and their uses
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
EP2978640A4 (en) Vehicular occupancy assessment
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL233934A0 (en) Antibodies to cd47, preparations containing them and their uses
EP3089994A4 (en) Fabs-in-tandem immunoglobulin and uses thereof
IL234710A (en) Antibodies that neutralize mpv, rsv, and pvm and their uses
EP3003390A4 (en) Anti-c10orf54 antibodies and uses thereof
EP2920742A4 (en) DEVICES, SYSTEMS AND METHOD FOR REINFORCING VISUAL ATTRIBUTES
EP3038723A4 (en) Pitch-propelled vehicle
EP2968503A4 (en) Anti-hepcidin antibodies and uses thereof
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL254416B (en) Anti-asic1 antibodies and their uses
EP2889173B8 (en) Vehicle
EP3028893A4 (en) Vehicle
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PL2650310T3 (pl) Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
EP3041826A4 (en) Triazolone compounds and uses thereof
EP2692621A3 (en) Saddle type vehicle
EP3003298A4 (en) Anti-fibrogenic compounds, methods and uses thereof
EP2998143A4 (en) Vehicle
EP2998142A4 (en) Vehicle
EP2998141A4 (en) Vehicle
HK1227906A1 (en) Fabs-in-tandem immunoglobulin and uses thereof
AU2012904723A0 (en) Free Parking iPhone App.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed